trial · primary record
4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2
B Cell Lymphoma (BCL)
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 11 |
| Primary completion | 2030-12-31 |
| Primary endpoint | Safety of fourth generation anti-CD19 and anti-CD20/CD22/CD70/PSMA/CD13/CD79b/GD2 CAR-T cells infusion |
| Registry ID | NCT04429438 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:42:51.011Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04429438
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.